Unlock instant, AI-driven research and patent intelligence for your innovation.

trk inhibitor, its preparation method and use

A dosage form and compound technology, applied in the field of medicine, achieves the effects of high product yield, mild reaction conditions and simple preparation method

Active Publication Date: 2021-05-18
FORELAND PHARM CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still room for improvement in the anti-tumor activity and pharmacokinetics of drugs under research such as LOXO-101

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • trk inhibitor, its preparation method and use
  • trk inhibitor, its preparation method and use
  • trk inhibitor, its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0104]

[0105] Intermediate 2: 6-fluoropyrazolo[1,5-a]pyrimidine-5,7-diol

[0106]

[0107] Under the protection of nitrogen, 2.0 g (24.1 mmol) of raw material 1a, 4.3 g (24.1 mmol) of raw material 1b and 7.3 g (48.2 mmol) of DBU were dissolved in 40 mL of 1,4-dioxane, and reacted at 110 ° C for 18 Hour. TLC detection, after the reaction, concentrated by rotary evaporation, added 20mL of ice water, under the protection of nitrogen, added about 14mL of 5M HCl to adjust the pH value of the solution to about 2, precipitated solid, stirred at low temperature, suction filtered, and vacuum-dried to obtain 2.27g of the product , gray solid, yield 55.7%. LC-MS: 168[M-1] + , t R = 0.416 min.

[0108] Intermediate 3: 5,7-Dichloro-6-fluoropyrazolo[1,5-a]pyrimidine

[0109]

[0110] Under nitrogen protection, 2g (11.8mmol) of intermediate 2 was dissolved in 20mL of phosphorus oxychloride, and then 2mL of N,N-dimethylaniline was added, the temperature was raised, and the rea...

Embodiment 1

[0126] Example 1: (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-6-fluoropyrazolo[1,5-a ]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

[0127]

[0128]Under the condition of nitrogen protection, 60 mg (0.18 mmol) of intermediate 8 and 29 mg of CDI were dissolved in 3 mL of 1,2-dichloroethane, and the temperature was raised to 65° C. to react overnight. Then 16 mg (0.18 mmol) (S)-3-pyrrolidinol (raw material 8a, dissolved in a small amount of 1,2-dichloroethane) and a drop of triethylamine were added, and the reaction was continued overnight at 65°C. TLC detection, after the reaction was completed, concentrated by rotary evaporation, and purified on a silica gel preparation plate (eluent DCM:MeOH=20:1) to obtain 16 mg of the product, a white solid, with a yield of 19.9%. LC-MS: 447.2[M+1] + , t R = 2.101 min.

[0129] 1 H NMR(400MHz,DMSO)δ9.98(s,1H),8.93(d,J=8.3Hz,1H),7.84(s,1H),7.29–6.98(m,4H),5.52(s,1H) , 4.97 (d, J=3.1Hz, 1H), 4.16–4.01 (m, 1H), 3.90–3.7...

preparation example 2

[0131]

[0132] Intermediate 22: 5-Bromo-3-nitropyrazolo[1,5-a]pyridine

[0133]

[0134] Suspend 200 mg of compound 21 in 1 ml of sulfuric acid and cool to 0°C. Add 0.5ml of sulfuric acid / 0.5ml of nitric acid mixture dropwise, and stir at 0°C for 30 minutes. TLC detection, after the reaction, poured into ice water, stirred for 10 minutes, and suction filtered to obtain 160 mg of white solid. used directly in the next reaction.

[0135] Intermediate 23: (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-nitropyrazolo[1,5-a]pyridine

[0136]

[0137] 160 mg (0.66 mmol) of compound 22, 140 mg (0.629 mmol) of compound 6a, 243 mg (1.89 mmol) of DIEA were dissolved in 5 mL of NMP, and reacted at 150° C. for 5 hours. TLC detection, after the reaction is over, add water and ethyl acetate to stir, let stand, separate layers, extract the aqueous phase with ethyl acetate, combine the organic phases to dry, and spin dry to obtain 0.7g of crude brown oil, which is directly used i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application belongs to the field of medicine, and specifically relates to a Trk inhibitor, its preparation method and application. The present invention mainly relates to compounds represented by the following formula A1, formula A2, formula A3 or formula A4, and pharmaceutically acceptable salts, stereoisomers, isotope labels, solvates, and polymorphic compounds of any compound in the compounds. Crystal form or prodrug, and preparation method and application of said compound

Description

technical field [0001] The application belongs to the field of medicine, and specifically relates to a Trk inhibitor, its preparation method and application. Background technique [0002] Tropomyosin Receptor Kinase (Trk) is classified as a receptor tyrosine kinase, which includes three members, TrkA, TrkB and TrkC. TrkA, TrkB and TrkC proteins are mainly encoded by NTrk1, NTrk2 and NTrk3 genes. All Trk receptors are highly expressed in nerve tissue and participate in the differentiation and maintenance of nerve cell function. Trk receptors are expressed in cancer cells, inflammatory cells, immune cells and keratinocytes, and can participate in the proliferation, migration and metastasis of cancer cells, inflammatory diseases, allergic diseases, pain, osteoporosis and bone metastasis and other disease processes . Therefore, the synthesis and development of new Trk inhibitors are of great significance for the treatment of diseases such as cancer, inflammatory diseases, all...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04C07D471/04C07D401/14A61P35/00A61P29/00A61P37/08A61P19/10A61P35/04A61K31/4709A61K31/4375A61K31/437A61K31/519
CPCA61P19/10A61P29/00A61P35/00A61P35/04A61P37/08C07B2200/07C07D401/14C07D471/04C07D487/04
Inventor 季奇高聪敏王磊巩龙龙陈博杜镇建
Owner FORELAND PHARM CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More